Cargando…

Genetic polymorphisms and ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy

Detalles Bibliográficos
Autores principales:	Tecza, Karolina, Pamula-Pilat, Jolanta, Kolosza, Zofia, Radlak, Natalia, Grzybowska, Ewa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4565546/ http://dx.doi.org/10.1186/1897-4287-13-S1-A4

Ejemplares similares

Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

Genetic polymorphisms, efficiency and toxicity of cancer chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

Copper transport system and response to ovarian cancer chemotherapy
por: Tecza, Karolina, et al.
Publicado: (2015)

Pharmacogenetics of FAC chemotherapy side effects in breast cancer patients
por: Tecza, Karolina, et al.
Publicado: (2015)

Genetic polymorphisms and response to 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients
por: Tecza, Karolina, et al.
Publicado: (2016)

Spectrum of tumors in the families with Hereditary Breast Ovarian Cancer syndrome carrying germline mutations in BRCA1 and 2 genes
por: Budryk, M, et al.
Publicado: (2012)

Pharmacogenetics of toxicity of 5-fluorouracil, doxorubicin and cyclophosphamide chemotherapy in breast cancer patients
por: Tecza, Karolina, et al.
Publicado: (2018)

Genetic 3′UTR variations and clinical factors significantly contribute to survival prediction and clinical response in breast cancer patients
por: Pamuła-Piłat, Jolanta, et al.
Publicado: (2020)

High-throughput genotyping of a common deletion polymorphism disrupting the TRY6 gene and its association with breast cancer risk
por: Wagner, Kerstin, et al.
Publicado: (2007)

Clinicopathological characteristics of breast cancer patients with NOD2 mutation according to age
por: Huszno, Joanna, et al.
Publicado: (2020)

Overall survival analysis of > 65-year-old patients with breast cancer based on their molecular, clinicopathological and laboratory factors
por: Huszno, Joanna, et al.
Publicado: (2022)

Paclitaxel and cisplatin chemotherapy for ovarian cancer during pregnancy: case report and review of the literature
por: Serkies, Krystyna, et al.
Publicado: (2011)

Gene Expression Analysis in Ovarian Cancer – Faults and Hints from DNA Microarray Study
por: Lisowska, Katarzyna Marta, et al.
Publicado: (2014)

Adriamycin-Cyclophosphamide (AC) followed by Paclitaxel-Cisplatin (PC). A highly active neoadjuvant regimen in locally advanced breast cancer
por: Mendoza-Posada, Daniel, et al.
Publicado: (2007)

Neoadjuvant chemotherapy with Cisplatin in BRCA1 mutation carriers – results of treatment
por: Byrski, T, et al.
Publicado: (2012)

First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence.
por: Sandercock, J., et al.
Publicado: (1998)

Systemic exposure to cisplatin and paclitaxel after intraperitoneal chemotherapy in ovarian cancer
por: de Jong, Loek A. W., et al.
Publicado: (2023)

The putative oncogene, CRNDE, is a negative prognostic factor in ovarian cancer patients
por: Szafron, Lukasz Michal, et al.
Publicado: (2015)

Functional Impact of Sequence Alterations Found in BRCA1 Promoter/5'UTR Region in Breast/Ovarian Cancer Families from Upper Silesia, Poland
por: Pamuła, Jolanta, et al.
Publicado: (2006)

Safety and Efficacy of Weekly Paclitaxel and Cisplatin Chemotherapy for Ovarian Cancer Patients with Hypersensitivity to Carboplatin
por: Tate, Shinichi, et al.
Publicado: (2021)

Identification of a genetic variant associated with treatment outcome in ovarian cancer: the potential role of cholesterol metabolism as a determinant of response to chemotherapy
por: Chenevix-Trench, Georgia, et al.
Publicado: (2012)

Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer
por: Huang, Chen-Yu, et al.
Publicado: (2020)

Functional polymorphisms in the TERT promoter are associated with risk of serious ovarian and breast cancer
por: Beesley, Jonathan, et al.
Publicado: (2012)

Prevalence of the most frequent BRCA1 mutations in Polish population
por: Brozek, Izabela, et al.
Publicado: (2011)

Effects of paclitaxel and cisplatin on in vitro ovarian follicle development
por: Kim, Yoon Young, et al.
Publicado: (2019)

Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational study
por: Coccolini, Federico, et al.
Publicado: (2015)

Polymorphisms and genetic susceptibility of type 1 diabetes mellitus and celiac disease
por: Bastos, Marília Dornelles, et al.
Publicado: (2015)

Cisplatin in breast cancer treatment in BRCA1 carriers
por: Gronwald, Jacek, et al.
Publicado: (2012)

Transcriptome Remodeling in Gradual Development of Inverse Resistance between Paclitaxel and Cisplatin in Ovarian Cancer Cells
por: Szenajch, Jolanta, et al.
Publicado: (2020)

Methotrexate (MTX) inhibition of cytokine production: relationship with clinical outcome and genetic polymorphisms
por: Sabina, P, et al.
Publicado: (2003)

Meeting abstracts from the Annual Conference on Hereditary Cancers 2015: Szczecin, Poland. 24-25 September, 2015
por: Thompson, Ella R., et al.
Publicado: (2017)

CNP attenuates renal toxicity induced by cisplatin in murine kidney
por: Kimura, Toru, et al.
Publicado: (2015)

Selenium and cancer – what have we learned from epidemiology and molecular epidemiology studies?
por: Jablonska, Ewa, et al.
Publicado: (2015)

Why choose the treatment with cisplatin for BRCA1 breast cancers patients?
por: Byrski, T, et al.
Publicado: (2012)

Neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
por: Byrski, T, et al.
Publicado: (2011)

Does the key to treat Rheumatoid nodules lie with oncology? - Is Cisplatin an option?
por: Omar, Eisha K, et al.
Publicado: (2013)

Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer
por: Ansaloni, L, et al.
Publicado: (2015)

Seizure following chemotherapy (paclitaxel and cisplatin) in a patient of carcinoma cervix
por: Dana, Rohitashwa, et al.
Publicado: (2016)

The risk factors of toxicity during chemotherapy and radiotherapy in breast cancer patients according to the presence of BRCA gene mutation
por: Huszno, Joanna, et al.
Publicado: (2015)

Association of CYP2D6*4 genetic polymorphism on the metabolism of Donepezil with Alzheimer's disease in Indian population
por: Subbiah, Vivekanandhan, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_hfo71hpum60dpalnol8rf30g2v